ロード中...
The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model
BACKGROUND: Tumor necrosis factor (TNF) antagonists [e.g., TNF soluble receptor (TNFsr)] improved survival in preclinical but not clinical sepsis trials. However fluid support—itself beneficial—is standard clinically but rarely employed in pre-clinical sepsis models. We hypothesized that these thera...
保存先:
主要な著者: | , , , , , , , , , |
---|---|
フォーマット: | Artigo |
言語: | Inglês |
出版事項: |
2011
|
主題: | |
オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3523295/ https://ncbi.nlm.nih.gov/pubmed/21922303 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00134-011-2324-z |
タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|